Many different, intersecting strategies are available for managing germ-cell cancers, particularly in early-stage disease. Which is right’ remains a matter of debate, and requires balancing efficacy against late effects, bearing in mind the complexity of [more]
The treatment of ovarian cancer and management of advanced ovarian cancer have progressed over the past few decades through several key milestones, including improvements in surgery, the evolution of chemotherapy and the establishment of an [more]
Non-small-cell lung cancers (NSCLC) covers a heterogeneous group of diseases, accounting for around 80% of all lung cancers, which were previously lumped together because there was no apparent reason to use different therapeutic approaches for [more]
New oncoplastic techniques are revolutionising the surgical management of breast cancer in much the same way that breast conserving surgery did in the 1970s. These technically demanding procedures are used as alternatives to mastectomy in [more]
Hormonal treatment remains a main stay of systemic therapy for prostate cancer despite recent developments in chemotherapy and intensive research with targeted drugs and immunotherapy. Its efficacy in palliative management of advanced disease has prompted [more]
Great strides have beenmade inmanaging patients with locally advanced squamous cell cancer of the head and neck over the past 20 years. Novel approaches using chemoradiation (CRT) have improved disease control and quality of life. [more]
The traditional approach to managing locally advanced rectal cancer has shifted to the concept of total mesorectal excision and the use of MRI for local staging and selecting patients for multimodal therapy. This case report [more]
Young oncologists want the chance to develop their skills, reach their full potential and give of their best. But a Cancer World survey shows many are frustrated by too heavy clinical workloads, too few chances [more]
Europe has money, human resources and a basic-science base that produces world-leading cancer research. Why, then, aren’t these assets being translated into clinical advances? Download full article
New technologies offer wonderful possibilities for cancer patients. But the development of personalised therapies is being squeezed between the priorities of industry and a regulatory system that offers poor value for money. Is there a [more]
The European School of Oncology marked the end of its 25th anniversary year by inviting a top-level line up of experts to debate, in front of the media, how effectively we are tackling cancer and [more]
Decades after breast screening programmes first started, their value remains hotly disputed. Some lives are saved, but it’s hard to tell how many. False-positives are a problem, but it’s a risk some are happy to [more]
After years of relying on 5FU, colorectal cancer clinicians now have a wealth of targeted therapies and combination protocols to choose from. The question is, what to use in which patients and when? Download full [more]